BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 36997402)

  • 1. PALB2 as a potential prognostic biomarker for colorectal cancer.
    Pan W; Lu K; Wang W; Yao J; Hou Y
    Comput Biol Chem; 2020 May; 87():107289. PubMed ID: 32497983
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Oldreive CE; Byrd PJ; Stewart GS; Taylor AJ; Farhat S; Skowronska A; Smith E; Raghavan M; Janic D; Dokmanovic L; Clokie S; Davies N; Kwok M; Pratt G; Paneesha S; Moss P; Stankovic T; Taylor M
    Leuk Lymphoma; 2019 Jul; 60(7):1823-1826. PubMed ID: 30614742
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
    Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    Xu H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2018 Jun; 18(1):662. PubMed ID: 29914420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
    Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Expression of PALB2 is Associated With Poor Survival in Chinese Women With Primary Breast Cancer.
    Liu J; Chen J; Sun J; Yao L; Zhang J; Xie Y; Xu Y
    Clin Breast Cancer; 2023 Jun; 23(4):e259-e266. PubMed ID: 36997402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PALB2, a major susceptibility gene for breast cancer].
    Piffer A; Luporsi E; Mathelin C
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
    Nepomuceno TC; De Gregoriis G; de Oliveira FMB; Suarez-Kurtz G; Monteiro AN; Carvalho MA
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.
    Tan W; Li Q; Chen K; Su F; Song E; Gong C
    Oncotarget; 2016 Mar; 7(9):10373-85. PubMed ID: 26863572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.